Artiva Biotherapeutics discontinues AlloNK development
Artiva Biotherapeutics announced a strategic update and discontinued development of AlloNK.
Related stories
European Q3 earnings growth forecast rises to 23.6%
LSEG IBES data puts expected Q3 earnings growth at 23.6%, versus 21.9% a week ago.
M impact | EQUITY | Oct 29, 2026, 02:56 PM UTC
Siniora Food Industries Reports Q3 Profit of 3.5 Million Dinars
M impact | EQUITY | Oct 29, 2026, 02:54 PM UTC
Barksdale Resources Raises CA$15.7 Million in Private Placement
Barksdale Resources closed the final tranche of its private placement, raising CA$15.7 million.
M impact | EQUITY | Oct 29, 2026, 02:54 PM UTC
Reliance Power Shares Gain 9.22%, Remain Down 59% in a Year
Reliance Power shares ended Thursday up 9.22%, while remaining 59% below their year-ago level.
M impact | EQUITY | Oct 29, 2026, 02:54 PM UTC
Noel Tata to Retire as Trent Chairman; Bahram Vakil to Succeed
Trent said Noel Tata will retire as chairman and director after business hours on November 11, 2026. The board appointed Bahram Vakil as chairman, effective November.
L impact | EQUITY | Oct 29, 2026, 02:53 PM UTC
Huntington Ingalls Industries Reports Quarterly Results
Huntington Ingalls Industries reported results for the quarter ended September 30; no figures were provided.
M impact | EQUITY | Oct 29, 2026, 02:53 PM UTC